TreviLogo.png
Trevi Therapeutics Announces Pricing of Initial Public Offering
May 07, 2019 13:22 ET | Trevi Therapeutics
NEW HAVEN, Conn., May 07, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to...